Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

Concert Pharmaceuticals Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Concert Pharmaceuticals (NASDAQ:CNCE) reported Q4 sales of $13.00 thousand. Earnings fell to a loss of $36.13 million, resulting in a 35.43% decrease from last quarter. In Q3, Concert Pharmaceuticals brought in $543.00 thousand in sales but lost $26.68 million in earnings.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.